28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
A total of 5 071 935 participants were included from 27 studies; approximately 49.2% of participants were female, and 14 studies were conducted in Asia, 7 in North America, 3 in Europe, and 3 in Oceania, represented by Australia. 5 key findings →
Design: systematic review Participants: 935 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A total of 3,056 participants without diabetes treatment and 480 with diabetes treatment were included (mean age at baseline, 75.1 years; mean 7.5 years of follow-up). 5 key findings →
Design: cohort study Participants: 3,056 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Huntington's disease patients had a lower prevalence of hypertension compared with age-matched gene-negative controls. 5 key findings →
Design: longitudinal study Participants: 14,534 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The prevalence of dementia worldwide is growing at an alarming rate. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Trajectories of systolic BP were separated markedly around 25 to 45 years of age, with the group below the median of cognition score having higher levels of systolic BP than the group above the median. 5 key findings →
Design: longitudinal study Participants: 912 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We report 1,136 cases of incident dementia among 4,166 individuals with nonmissing APOE status. 5 key findings →
Design: cohort study Participants: 4,166 Evidence: moderate
Full summary, score breakdown and related studies → Original source
At study entry, the mean (SD) age of the participants was 70 (SD, 8.9) years and 41% were males. 5 key findings →
Design: longitudinal study Participants: 555 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In the first year of follow-up, increased exposure to all air pollutants was associated with an increase in the use of CMHTs in a dose-response manner. 5 key findings →
Design: longitudinal study Participants: 5,024 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this systematic review and meta-analysis, estimates indicate that FTD is comparable in frequency to dementia with Lewy bodies and occurs at higher rates than progressive supranuclear palsy, corticobasal syndrome, and amyotrophic lateral sclerosis. 5 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From the 868 Framingham Heart Study participants who returned for a second PSG, this cohort included 346 participants with a mean age of 69 years (range, 60-87 years); 179 (52%) were female. 4 key findings →
Design: cohort Participants: 346 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
Of 23 558 people without pre-existing dementia, 4135 (17·6%) had an admission with delirium. 5 key findings →
Design: cohort Participants: 23,558 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Frailty, comorbidities, and other age-related diseases were associated with a higher risk of dementia but did not account for the elevated dementia risk observed after severe infections. 3 key findings →
Design: cohort Participants: 449,223 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease and coronary artery disease are common late-life chronic conditions and share multiple risk factors, including the apolipoprotein E (APOE) ε4 allele. 4 key findings →
Design: RCT Participants: 1,177 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Fasting lipid fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC]) were studied as continuous variables, and results are reported per SD increase of each lipid fraction. 5 key findings →
Design: cohort study Participants: 9,294 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with ε4 on the APOE gene, which mitigates the ε4-associated AD risk. 5 key findings →
Design: case-control study Participants: 37 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Blood pressure variability (BPV) has been shown to have predictive value over blood pressure (BP) levels alone in stroke patients. 3 key findings →
Design: randomized controlled trial Participants: 460 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Our results suggest that higher glucose levels may be a risk factor for dementia, even among persons without diabetes. 4 key findings →
Participants: 839 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
As there is currently no cure for dementia, there is an urgent need for preventive strategies. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diabetes prevention and glucose control in midlife may protect against late-life cognitive decline. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A systematic review was conducted to identify risk factors associated with the onset and progression of Alzheimer's disease (AD). 5 key findings →
Design: systematic review Participants: 65 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A combination of modifiable vascular risk factors in midlife is highly predictive of the likelihood of dementia decades later. 1 key finding →
Design: cohort study Participants: 2,767 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Atrial fibrillation, hypertension, and angina were associated with a greater rate of decline and may represent modifiable risk factors for secondary prevention in Alzheimer disease. 3 key findings →
Design: longitudinal study Participants: 135 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our results suggest that having an increased body weight or abdominal obesity are associated with increased dementia incidence. 5 key findings →
Design: longitudinal study Participants: 453 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Main results Four trials including 15,936 hypertensive subjects were identified. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
We tested whether dysregulation of cholesterol catabolism, through its conversion to primary bile acids (BAs), was associated with dementia pathogenesis. 5 key findings →
Design: cohort study Participants: 141 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
10 of the 3,281 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →